1Locarnini S, Hatzakis A, Heathcote J, et al. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther ,2004,9:679-693.
2Lai CL, Gane E, Hsu CW, et al. Tebivudine vs lamivudine in HBeAg positive with CHB: two year efficacy and predictors of response. Hepatol Int, 2007,1:13.
3Hou JL, Jia JD, Yin YK, et al. A phase Ⅲ comparative trial of tebivudine vs lamivudine in Chinese patients: two year results. Hepatol Int, 2007,1 : 13.
4Liaw YF. Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology, 2007,45:266-268.
5Sun J, Wang Z, Ma S, et al. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience. J Med Virol, 2005,75 : 391- 398.
6Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology, 2005,42: 1414- 1419.
7Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching to adefovir therapy in lamivudine resistant HB e antigen-negative chronic hepatitis B. Hepatology, 2007, 45: 307-313.
8Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology, 2006,44:703-712.
